The chemoprevention of caner is defined as the use of chemical and natural products to prevent, delay or reverse the carcinogenesis. A new horizon in chemoprevention research is the discovery of molecular links between inflammation and cancer. The modulation of inappropriate cell signaling pathways might be a rational approach in achieving chemoprevention. The one of prime targets for the development of new chemopreventive agents is the TGF-ß signaling pathway. TGF-ß has a pivotal role in the regulation of a wide variety of physiological processes from development to pathogenesis. Alterations of TGF-ß signaling in pathological conditions cause a variety of human disease, including cancers and tissue fibrosis. The modulation of TGF-ß signaling by small molecules can provide efficacious and specific intervention in disease processes. The primary goals of our group are to discover novel chemopreventive molecular targets and develop drug candidates against cancer and/or inflammation. |
Development and target identification for chemoprevention in TGF-ß signaling pathway |
Screening of TGF-ß signal modulators from natural and synthetic compounds |
- Screening of specific Smad activity modulators - Screening of regulators of inhibitory Smads for anti-inflammation - Discovery of novel TGF-ß receptor kinase inhibitors using virtual screening |
Molecular mechanism of TGF-ß receptor stability by HSP90 inhibitors and the role of HSP chaperone in TGF-ß signaling |
Identification of molecular targets for driving reversing epithelial-mesenchymal transition (EMT) |
Our research is focused on the understanding of the signaling mechanisms of TGF-b and the identification of molecular targets for chemopreventives and/or chemotherapeutics using small molecules. Based on these findings, we will develop novel therapeutic drug candidates against cancer and/or inflammation.